Five patients (29.4%), all with KMT2A-r AML, had received prior menin inhibitors as part of clinical trials (2 patients had received revumenib, one patient each had received ziftomenib and bleximenib and one patient had received both revumenib and ziftomenib). This evidence concerns the gene MEN1 and acute myeloid leukemia.